Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 4

Results For "cell-therapy"

91 News Found

USFDA approves Bristol Myers and 2seventy bio’s Abecma for triple-class exposed multiple myeloma
Drug Approval | April 06, 2024

USFDA approves Bristol Myers and 2seventy bio’s Abecma for triple-class exposed multiple myeloma

Abecma tripled progression-free survival compared to standard regimens in the Phase 3 KarMMa-3 trial


BlueRock Therapeutics Phase I clinical trial for Parkinson’s disease continues to show positive trends
Diagnostic Center | March 06, 2024

BlueRock Therapeutics Phase I clinical trial for Parkinson’s disease continues to show positive trends

Investigational cell therapy bemdaneprocel continues to be well tolerated with no major safety issues in all 12 participants in low and high dose cohorts through 18 months


AstraZeneca completes acquisition of Gracell
News | February 23, 2024

AstraZeneca completes acquisition of Gracell

The acquisition enriches AstraZeneca’s growing pipeline of cell therapies with GC012F


YS Biopharma appoints new Directors
People | February 17, 2024

YS Biopharma appoints new Directors

The Board has elected Dr. Ajit Shetty, who had served as the Company's Interim Chairperson of the Board since December 9, 2023, as Chairperson of the Board, effective February 13, 2024


NATCO invests US$ 2 million in Cellogen Therapeutics
News | January 18, 2024

NATCO invests US$ 2 million in Cellogen Therapeutics

Both these innovations are aimed at reducing the risk of relapse post CAR T cell therapy


Cipla announces JV with Kemwell Biopharma and Manipal Education & Medical Group
News | January 09, 2024

Cipla announces JV with Kemwell Biopharma and Manipal Education & Medical Group

The primary goal of this joint venture is to develop and commercialise novel cell therapy products for major unmet medical needs in the United States, Japan, and EU regions


Cipla EU to form JV in USA
News | January 07, 2024

Cipla EU to form JV in USA


Cell and gene therapy will be top industry trend for pharma in 2024, finds GlobalData
News | January 02, 2024

Cell and gene therapy will be top industry trend for pharma in 2024, finds GlobalData

The survey data presented in “The State of the Biopharmaceutical Industry 2024” report reveals that N=21 (18%) of industry professionals were convinced that CGT will dominate as the most important trend in pharma next year


AstraZeneca to acquire China's Gracell Biotechnologies for US $1.2 billion
News | December 26, 2023

AstraZeneca to acquire China's Gracell Biotechnologies for US $1.2 billion

Furthering cell therapy ambition across oncology and autoimmune diseases


Vertex and CRISPR Therapeutics announce USFDA approval of Casgevy for treatment of sickle cell disease
Drug Approval | December 09, 2023

Vertex and CRISPR Therapeutics announce USFDA approval of Casgevy for treatment of sickle cell disease

Approximately 16,000 patients 12 years of age and older with severe sickle cell disease may now be eligible for this one-time treatment